Today: 17 April 2026
Salesforce stock steadies premarket after 7% drop as AI worries shadow Slackbot rollout
14 January 2026
2 mins read

Salesforce stock steadies premarket after 7% drop as AI worries shadow Slackbot rollout

New York, Jan 14, 2026, 05:05 (ET) — Premarket

Salesforce (CRM.N) stock was steady near $241 in U.S. premarket trading Wednesday, following a steep drop the day before. The cloud software company closed Tuesday down 7.07% at $241.06, with shares swinging between $260.91 and $240.35 on roughly 13.7 million shares traded.

Salesforce’s role is key, given its weight in major U.S. indexes and its status as a gauge of investor sentiment on the next wave of enterprise AI investment. On Tuesday, the Dow dropped roughly 1%, with Salesforce and Visa standing out as some of the biggest drags, according to a MarketWatch Dow Jones data note.

Traders are grappling with a tougher question: is AI boosting software demand, or enabling firms to accomplish the same tasks with fewer licenses? MarketWatch pointed out the selloff also stemmed from a shift into semiconductor stocks and a wider reassessment of software names. Adobe took a hit after an analyst downgrade piled on the pressure.

Salesforce announced Tuesday that a redesigned Slackbot—now positioned as a personal agent within Slack—is officially rolling out to Business+ and Enterprise+ customers. The rollout will roll out in phases through January and February. “Slackbot … is the front door to the Agentic Enterprise,” said Parker Harris, Salesforce co-founder and Slack’s CTO. Enterprise admins can control access permissions or limit use until Feb. 10. Business Wire

AI “agents” aim to outdo chatbots by not only answering questions but also pulling data, drafting text, and triggering actions across various tools on demand. For investors, the appeal is straightforward: productivity gains. Still, the trade has seen volatility since the returns are tougher to quantify.

Salesforce has been pushing its AI agent platform, Agentforce, hard and claims the market is finally responding. Back in December, the company boosted its fiscal 2026 revenue and adjusted profit targets. CEO Marc Benioff revealed that Agentforce and Data 360 are closing in on $1.4 billion in annual recurring revenue (ARR), a subscription-based figure that annualizes contracted revenue. “Raising guidance for year-end shows the confidence it has in pipeline,” said Rebecca Wettemann, CEO of analyst firm Valoir. Reuters

Timing is delicate. As earnings season hits its stride, analysts forecast an 8.8% year-on-year profit jump for the S&P 500 in Q4, with tech stocks expected to take the lead, Reuters reported. That sets the stage for heightened sensitivity to any signs of growth faltering or cautious guidance.

Product launches alone won’t bridge the gap. If customers delay AI deployments, resist higher prices, or leverage AI to cut software seats rather than expand them, the risk shifts from theoretical to a real threat tied to renewals and budgets.

Traders will keep an eye on whether Tuesday’s drop extends to other enterprise software stocks at the open, and if bargain hunters jump in. New analyst calls on IT budgets and AI returns could trigger swift moves in the sector.

Salesforce’s quarterly report on March 4, after the close, is the next major milestone, according to TipRanks. Investors are focused on updates around Agentforce demand, margins, and how quickly new bookings are coming in.

Stock Market Today

  • Hims & Hers Health Shares Jump 11.1% on FDA News, Future Gains Uncertain
    April 17, 2026, 8:12 AM EDT. Hims & Hers Health (HIMS) stock surged 11.1% to close at $26.99 amid high trading volume, driven by optimism after the FDA announced a discussion on peptide drugs used for conditions like opioid use disorder and insomnia. The company recently acquired a California peptide facility to bolster its U.S. supply chain. Despite expected quarterly earnings of $0.06 per share, down 70% year-over-year, revenues are projected to rise 6% to $621.4 million. The consensus earnings estimate held steady in the past month, suggesting limited near-term momentum. HIMS holds a Zacks Rank #3 (Hold). Investors should monitor earnings estimate revisions to gauge further upside potential.

Latest article

XRP Price Today: XRP Climbs to $1.44 as ETF Inflows, Risk-On Mood Lift Ripple-Linked Token

XRP Price Today: XRP Climbs to $1.44 as ETF Inflows, Risk-On Mood Lift Ripple-Linked Token

17 April 2026
XRP climbed to about $1.44 in early New York trading Friday, up 2.5% in 24 hours with turnover over $4 billion, outpacing bitcoin and ether. U.S.-listed spot XRP ETFs saw $17 million in net inflows on April 15, the highest since February. Ripple announced a partnership with Kyobo Life Insurance for Korea’s first tokenised government bond settlement project. XRP remains about 60% below its all-time high.
Gold Price Today Near $4,784 as Weaker Dollar Keeps Bullion on Track for Fourth Weekly Gain

Gold Price Today Near $4,784 as Weaker Dollar Keeps Bullion on Track for Fourth Weekly Gain

17 April 2026
Gold hovered near $4,784 an ounce Friday, set for a fourth weekly gain despite easing 0.1% by 0815 GMT. A 10-day Lebanon-Israel ceasefire and possible U.S.-Iran talks kept investors watching for diplomatic progress. Indian gold imports stalled as banks await new government authorization, leaving over 5 tons stuck at customs. Spot silver rose 0.7% to $78.97, platinum held steady, and palladium slipped 0.1%.
Smith & Nephew stock drops in London as investors size up $450m Integrity Orthopaedics deal
Previous Story

Smith & Nephew stock drops in London as investors size up $450m Integrity Orthopaedics deal

Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next
Next Story

Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

Go toTop